NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Joe Biden
    United States of America
    COVID-19
    Russia-Ukraine crisis
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / World News / Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
    World

    Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine

    Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
    Written by Sagar
    Jan 25, 2022, 07:55 pm 2 min read
    Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
    Pfizer and BioNTech could file for a regulatory approval of their Omicron-specific vaccine by March.

    Pfizer and BioNTech have begin the clinical trial for a vaccine against the Omicron variant of coronavirus, the companies said on Tuesday. The trial will test the shot for safety, tolerability, and the level of immune response it would trigger. The companies could be ready to file for a regulatory approval of the vaccine by March, according to Pfizer CEO Albert Bourla.

    Why does this story matter?

    • The Pfizer's vaccine's trial data will be crucial in understanding the need for variant-specific vaccines.
    • Omicron, in particular, is the most highly infectious coronavirus strain so far and has triggered outbreaks in many countries around the world.
    • Several affected nations, however, are now showing signs of recovery from the latest wave.
    • COVID-19 has claimed the lives of over 50 lakh since the disease surfaced.

    Trial involves 1,400+ adults

    The trial for the Omicron-specific vaccine involves 1,420 healthy adults aged between 18 and 55 years. It will be administered to the participants as a 30-microgram dose, the same as the existing Pfizer vaccine. The Pfizer-BioNTech vaccine, which is based on messenger RNA technology, was notably the first COVID-19 shot to be authorized in the United States, in December 2020.

    Participants split into three groups

    According to the companies, the participants are divided into three groups: 1) Those who have received two doses of the current Pfizer vaccine at least 90-180 days before the trial. 2) Those who have received three doses of the current Pfizer vaccine at least 90-180 days before the trial. 3) Those who have not received any coronavirus vaccine.

    'We need to be prepared'

    Pfizer's Kathrin Jansen said the company is acting out of caution. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," she stated.

    Some experts opine against such shots

    However, some experts argue that an Omicron-specific vaccine may become redundant by the time it is produced at a large scale. They say drug makers should invest in developing vaccines that can target several different variants. "What's really game-changing would be a universal coronavirus vaccine that targets a conserved area of all human coronaviruses," Amesh Adalja, an infectious disease specialist, said, according to FT.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    Pfizer
    BioNTech
    Omicron variant

    Latest

    Airtel 5G launched in more cities across Gujarat, Odisha Bharti Airtel
    'Farzi' to 'Thunivu': Exciting OTT weekend watchlist is here OTT releases
    Here's how to come out of a toxic relationship  Relationships
    Lifeguards in Goa get AI assistance for rescue operations Goa

    Pfizer

    Biden tests positive for COVID-19; rare case of 'rebound positivity' World
    New Omicron sub-variants can trigger new COVID-19 wave: Study World
    'Cautious optimism' after initial Omicron studies; here's what we know Technology
    COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective Technology

    BioNTech

    Pfizer-BioNTech vaccine 'safe' for kids aged 5-11; generates 'robust immunity' Pfizer
    England school children aged 12-15yrs to be offered COVID-19 vaccine Pfizer
    US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA Pfizer
    Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week Pfizer

    Omicron variant

    Omicron subvariant XBB.1.5: What do we know so far COVID-19
    COVID-19: WHO urges travelers to mask up amid XBB.1.5 spread World Health Organization
    China slams 'distorted' Western reports on COVID-19 response, eases restrictions China
    COVID-19: Mock drills across India to test preparedness; more updates COVID-19

    Love World News?

    Subscribe to stay updated.

    World Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023